Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rheumatology

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

Valeant offers $2.6bn to buy dermatology firm Medicis

Possible further addition to long list of Canadian pharma firm’s acquisitions

Bristol-Myers Squibb (BMS) building

BMS halts hep C candidate development after patient death

Promises to share drug data to assist other pharma companies’ patient safety measures

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

Bristol-Myers Squibb (BMS) building

BMS halts trial of hepatitis C drug on safety issues

At least one person in study thought to have developed congestive heart failure

- PMLiVE

Pfizer sells Kent R&D centre to property consortium

Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links